Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
I. Škopljanac (Split, Croatia), I. Segrt (Split, Croatia), K. Mise (Split, Croatia), E. Lozo Vukovac (Split, Croatia), A. Tolic Biocina (Split, Croatia). Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma. 2894

Member's Comments

No comment yet.

Related content which might interest you: Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Videothoracoscopy in diagnosis and palliative treatment of malignant pleural mesothelioma Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008 Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 Role of surgery and of radiotherapy in malignant pleural mesothelioma Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011 Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Malignant mesothelioma and chemotherapy: efficacy and influence on survival of patients Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Is prophylactic radiotherapy at intervention site always neccessary in malign pleural mesothelioma? Source: Eur Respir J 2006; 28: Suppl. 50, 751s Year: 2006 Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 754s Year: 2007 Extrapleural pneumonectomy versus pleurectomy/decortication in malignant pleural mesothelioma: an updated meta-analysis of survival endpoints Source: International Congress 2019 – All aspects of general thoracic surgery Year: 2019 Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Multimodal therapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Polychemotherapy experience in pleural mesothelioma with or without pemetrexed Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Multimodality therapy for malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Thoracoscopic palliative treatment of malignant pleural effusions Source: Annual Congress 2011 - A little bit of everything: interventional pneumology Year: 2011